GoodRx Expands Cash-Pay Access to Oral Ozempic for Patients With Type 2 Diabetes

GoodRx announced it will offer access to the Ozempic pill, an oral semaglutide option for patients with type 2 diabetes, expanding its role in the evolving GLP-1 access landscape with a new self-pay offering at pharmacies nationwide.¹ The move reflects continued growth in alternative distribution and pricing pathways for high-demand metabolic therapies, particularly as oral formulations begin to complement established injectable treatments.

In a May 1st announcement, GoodRx said eligible patients can obtain the oral GLP-1 therapy through its nationwide pharmacy network using transparent, self-pay pricing tiers.¹ The program is positioned as a direct-to-patient access pathway outside of traditional insurance adjudication, with an emphasis on affordability and predictable out-of-pocket costs.

“The availability of an oral formulation under the Ozempic brand marks an important step forward, offering a convenient alternative to the established injectable,” said Wendy Barnes, president and CEO of GoodRx, in a release.¹ “It also reflects GoodRx’s expanding work with Novo Nordisk across the entire semaglutide portfolio and its role in supporting patient access.”

The Ozempic pill is available on the site to eligible self-pay patients at a cash price of $149 per month for the 1.5mg dose, $199 per month for the 4mg dose, and $299 per month for the 9mg dose.¹

Why Does Oral GLP-1 Access Matter?

GLP-1 receptor agonists are widely used in type 2 diabetes management due to their ability to improve glycemic control. Their clinical utility has also contributed to increased demand across the class. However, access barriers remain, particularly related to cost. Evidence from a large claims-based study in JAMA Network Open found that higher out-of-pocket costs for GLP-1 receptor agonists are associated with a lower likelihood of treatment initiation in patients with type 2 diabetes, indicating that affordability can significantly influence whether patients start these therapies.²

Oral semaglutide introduces a different delivery modality within the class. Unlike injectable GLP-1 therapies, it is administered as a tablet, offering a non-injectable option for patients prescribed semaglutide. Clinical literature notes that oral administration “has the potential to increase usage of GLP-1RAs in the primary care setting by addressing clinician and patient concerns about injections.”³

How Are GLP-1 Access and Distribution Models Changing?

GoodRx’s new offering highlights how access to GLP-1 therapies is increasingly distributed across multiple channels rather than relying exclusively on insurance reimbursement. Traditional payer pathways remain central, but cash-pay models, pharmacy discount platforms, and telehealth-enabled prescribing have expanded the number of ways patients can obtain therapy.

At the same time, oral formulations may reduce certain operational requirements associated with injectable biologics, which typically involve device-based administration systems.³ While injectables remain a core modality within the GLP-1 class, oral options expand flexibility in prescribing and dispensing workflows.

What’s the Bottom Line?

GoodRx’s introduction of an oral semaglutide access pathway for type 2 diabetes patients reflects broader changes in how GLP-1 therapies are accessed and distributed. Rather than relying solely on insurance-based reimbursement systems, patients now encounter a growing mix of cash-pay platforms, pharmacy networks, and telehealth-enabled services.

As oral GLP-1 formulations become more widely available, and as alternative pricing models continue to evolve, access to these therapies is becoming more modular.

References

1. GoodRx. GoodRx expands offerings to include oral semaglutide option for type 2 diabetes patients. May 1, 2026. Accessed May 1, 2026. https://investors.goodrx.com/news-releases/news-release-details/goodrx-expands-offerings-now-include-ozempicr-pill-type-2
2. Luo J, Feldman R, Korytkowski M, et al. Evaluation of out-of-pocket costs and treatment intensification with an SGLT2 inhibitor or GLP-1 receptor agonist in patients with type 2 diabetes and cardiovascular disease. JAMA Network Open. 2023;6(6):e2317113. doi:10.1001/jamanetworkopen.2023.17113
   https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805937
3. Morales J, Shubrook JH, Skolnik N. Practical guidance for use of oral semaglutide in primary care: a narrative review. Postgraduate Medicine. 2020;132(8):687-696. doi:10.1080/00325481.2020.1788340. https://pubmed.ncbi.nlm.nih.gov/32643514/